A RealClear Health column urges FDA not to overcorrect as it reconsiders its approach to investigational rare disease therapies.
Gilead petitions FDA to rescind its acceptance for filing of two Zydus 505(b)(2) applications for drugs that Gilead says are duplicates of its Descovy and Vemlidy.
A RealClear Health column urges FDA not to overcorrect as it reconsiders its approach to investigational rare disease therapies.
Gilead petitions FDA to rescind its acceptance for filing of two Zydus 505(b)(2) applications for drugs that Gilead says are duplicates of its Descovy and Vemlidy.
FDA clears a Neptune Medical 510(k) for its Triton 1 System, a robotic system for next-generation flexible endoscopy.
Sen. Elizabeth Warren says she is continuing to push Trump officials to release the actual contracts that have been signed with drug companies that are participating in the TrumpRx drug price reductions.
